J Lee Villano1, Eric B Durbin1, Chris Normandeau1, Jigisha P Thakkar1, Valentina Moirangthem1, Faith G Davis1. 1. Departments of Medicine and Neurology, University of Kentucky, Lexington, Kentucky (J.L.V., J.P.T.); Department of Medicine, University of Kentucky, Lexington, Kentucky (V.M.); Department of Biostatistics, University of Kentucky, Lexington, Kentucky (E.B.D.); School of Public Health, University of Alberta, Edmonton, Canada (C.N., F.G.D.); Alberta Health Services, Edmonton, Canada (C.N.).
Abstract
BACKGROUND: No reliable estimates are available on the incidence of brain metastasis (BM) in cancer patients. This information is valuable for planning patient care and developing measures that may prevent or decrease the likelihood of metastatic brain disease. METHODS: We report the first population-based analysis on BM incidence at cancer diagnosis using the Kentucky Cancer Registry (KCR) and Alberta Cancer Registry (ACR). All cancer cases with BM were identified from KCR and ACR, with subsequent focus on metastases from lung primaries; the annual number of BMs at initial presentation was derived. Comparisons were made between Kentucky and Alberta for the stage and site of organ involvement of lung cancer. RESULTS: Low incidence of BM was observed in the United States until mandatory reporting began in 2010. Both the KCR and ACR recorded the highest incidence of BM from lung cancer, with total BM cases at initial presentation occurring at 88% and 77%, respectively. For lung cancer, stage IV was the most common stage at presentation for both registries and ranged from 45.9% to 57.2%. When BM from lung was identified, the most common synchronous organ site of metastasis was osseous, occurring at 28.4%. CONCLUSION: Our analysis from the Kentucky and Alberta cancer registries similarly demonstrated the aggressive nature of lung cancer and its propensity for BM at initial presentation. Besides widespread organ involvement, no synchronous organ site predicted BM in lung cancer. BM is a common and important clinical outcome, and use of registry data is becoming more available.
BACKGROUND: No reliable estimates are available on the incidence of brain metastasis (BM) in cancerpatients. This information is valuable for planning patient care and developing measures that may prevent or decrease the likelihood of metastatic brain disease. METHODS: We report the first population-based analysis on BM incidence at cancer diagnosis using the Kentucky Cancer Registry (KCR) and Alberta Cancer Registry (ACR). All cancer cases with BM were identified from KCR and ACR, with subsequent focus on metastases from lung primaries; the annual number of BMs at initial presentation was derived. Comparisons were made between Kentucky and Alberta for the stage and site of organ involvement of lung cancer. RESULTS: Low incidence of BM was observed in the United States until mandatory reporting began in 2010. Both the KCR and ACR recorded the highest incidence of BM from lung cancer, with total BM cases at initial presentation occurring at 88% and 77%, respectively. For lung cancer, stage IV was the most common stage at presentation for both registries and ranged from 45.9% to 57.2%. When BM from lung was identified, the most common synchronous organ site of metastasis was osseous, occurring at 28.4%. CONCLUSION: Our analysis from the Kentucky and Alberta cancer registries similarly demonstrated the aggressive nature of lung cancer and its propensity for BM at initial presentation. Besides widespread organ involvement, no synchronous organ site predicted BM in lung cancer. BM is a common and important clinical outcome, and use of registry data is becoming more available.
Authors: Laurie E Gaspar; Kari Chansky; Kathy S Albain; Eric Vallieres; Valerie Rusch; John J Crowley; Robert B Livingston; David R Gandara Journal: J Clin Oncol Date: 2005-05-01 Impact factor: 44.544
Authors: B C Pestalozzi; D Zahrieh; K N Price; S B Holmberg; J Lindtner; J Collins; D Crivellari; M F Fey; E Murray; O Pagani; E Simoncini; M Castiglione-Gertsch; R D Gelber; A S Coates; A Goldhirsch Journal: Ann Oncol Date: 2006-04-07 Impact factor: 32.976
Authors: Jill S Barnholtz-Sloan; Andrew E Sloan; Faith G Davis; Fawn D Vigneau; Ping Lai; Raymond E Sawaya Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Paul W Sperduto; T Jonathan Yang; Kathryn Beal; Hubert Pan; Paul D Brown; Ananta Bangdiwala; Ryan Shanley; Norman Yeh; Laurie E Gaspar; Steve Braunstein; Penny Sneed; John Boyle; John P Kirkpatrick; Kimberley S Mak; Helen A Shih; Alex Engelman; David Roberge; Nils D Arvold; Brian Alexander; Mark M Awad; Joseph Contessa; Veronica Chiang; John Hardie; Daniel Ma; Emil Lou; William Sperduto; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2016-06-14 Impact factor: 7.038
Authors: Courtney Kromer; Jordan Xu; Quinn T Ostrom; Haley Gittleman; Carol Kruchko; Raymond Sawaya; Jill S Barnholtz-Sloan Journal: J Neurooncol Date: 2017-05-31 Impact factor: 4.130
Authors: Priscila H Goncalves; Stephanie L Peterson; Fawn D Vigneau; Ronald D Shore; William O Quarshie; Khairul Islam; Ann G Schwartz; Antoinette J Wozniak; Shirish M Gadgeel Journal: Cancer Date: 2016-04-08 Impact factor: 6.860
Authors: Lakshmi Nayak; Lisa M DeAngelis; H Ian Robins; Ramaswamy Govindan; Shirish Gadgeel; Karen Kelly; James R Rigas; David M Peereboom; Steven S Rosenfeld; Alona Muzikansky; Ming Zheng; Patrick Urban; Lauren E Abrey; Antonio Omuro; Patrick Y Wen Journal: Cancer Date: 2015-08-26 Impact factor: 6.860